4/22
08:09 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $30.00 price target on the stock.
Neutral
Report
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $30.00 price target on the stock.
4/17
04:19 pm
etnb
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors [Yahoo! Finance]
Medium
Report
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors [Yahoo! Finance]
4/17
04:05 pm
etnb
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
Medium
Report
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
4/5
04:17 pm
etnb
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
4/5
04:05 pm
etnb
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/5
10:25 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $29.00 price target on the stock.
Low
Report
89bio, Inc. (NASDAQ: ETNB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $29.00 price target on the stock.
3/27
02:11 pm
etnb
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $31.00 price target on the stock.
Low
Report
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $31.00 price target on the stock.
3/27
08:21 am
etnb
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis [Yahoo! Finance]
Low
Report
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis [Yahoo! Finance]
3/27
08:00 am
etnb
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
Low
Report
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
3/18
03:14 pm
etnb
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $31.00 price target on the stock.
Low
Report
89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $31.00 price target on the stock.
3/12
08:17 am
etnb
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis [Yahoo! Finance]
Low
Report
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis [Yahoo! Finance]
3/12
08:00 am
etnb
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
Low
Report
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
3/8
04:05 pm
etnb
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3/6
02:35 pm
etnb
89bio, Inc. (NASDAQ: ETNB) had its price target raised by analysts at Evercore ISI from $29.00 to $37.00. They now have an "outperform" rating on the stock.
Low
Report
89bio, Inc. (NASDAQ: ETNB) had its price target raised by analysts at Evercore ISI from $29.00 to $37.00. They now have an "outperform" rating on the stock.
3/5
04:05 pm
etnb
89bio to Participate in the Leerink Partners Global Biopharma Conference
Medium
Report
89bio to Participate in the Leerink Partners Global Biopharma Conference
3/5
08:14 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
High
Report
89bio, Inc. (NASDAQ: ETNB) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
3/4
10:18 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $29.00 price target on the stock.
High
Report
89bio, Inc. (NASDAQ: ETNB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $29.00 price target on the stock.
3/2
04:51 am
etnb
89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ... [Yahoo! Finance]
High
Report
89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ... [Yahoo! Finance]
3/1
10:31 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at Royal Bank of Canada from $15.00 to $14.00. They now have a "sector perform" rating on the stock.
Low
Report
89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at Royal Bank of Canada from $15.00 to $14.00. They now have a "sector perform" rating on the stock.
3/1
08:13 am
etnb
89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at HC Wainwright from $32.00 to $31.00. They now have a "buy" rating on the stock.
Medium
Report
89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at HC Wainwright from $32.00 to $31.00. They now have a "buy" rating on the stock.
2/29
04:26 pm
etnb
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates [Yahoo! Finance]
High
Report
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates [Yahoo! Finance]
2/29
04:05 pm
etnb
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
High
Report
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
2/6
04:05 pm
etnb
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Low
Report
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/5
04:16 pm
etnb
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
High
Report
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
2/5
04:05 pm
etnb
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)